Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Operating Leases for 4 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 37.31% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 37.31% decrease, with the full-year FY2025 number at $4.0 million, down 37.31% from a year prior.
  • Operating Leases was $4.0 million for Q4 2025 at Fulcrum Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $12.8 million in Q1 2022 to a low of $4.0 million in Q4 2025.
  • A 4-year average of $8.4 million and a median of $8.4 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: fell 20.05% in 2024, then plummeted 37.31% in 2025.
  • Fulcrum Therapeutics' Operating Leases stood at $10.8 million in 2022, then decreased by 20.26% to $8.6 million in 2023, then decreased by 25.33% to $6.4 million in 2024, then tumbled by 37.31% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Operating Leases are $4.0 million (Q4 2025), $4.7 million (Q3 2025), and $5.3 million (Q2 2025).